Journal: Journal of Fungi

Article Title: Development of a Simple and Robust Whole Blood Assay with Dual Co-Stimulation to Quantify the Release of T-Cellular Signature Cytokines in Response to Aspergillus fumigatus Antigens

doi: 10.3390/jof7060462

Figure Lengend Snippet: Comparison of Aspergillus -induced cytokine release in patients with Aspergillus -associated lung pathologies and other chronic lung diseases. WB from 9 patients with Aspergillus -associated lung pathologies (2 CF with A. fumigatus sensitization, 3 ABPA, and 4 CPA) and a control group of 5 patients with other chronic lung diseases was stimulated with AfuLy or Aspf4 using the RPMI-supplemented, α-CD28-, and α-CD49d-containing stimulation tubes, as described in the Materials and Methods Section. Cytokine concentrations in plasma supernatants were quantified using a 21-plex Luminex assay. ( a , b ) Heat maps indicating median background-adjusted cytokine concentrations in the ABPA/CF/CPA patient cohort “A” and control cohort “C” depending on the antigen used for stimulation. The numeric value in the MMR column represents the median-to-median ratio between the two cohorts, with values > 1.0 indicating greater median cytokine concentrations in the ABPA/CF/CPA cohort. Δ denotes infinite median-to-median ratios (median = 0 pg/mL in the control cohort). ◊ denotes undefined median-to-median ratios (median = 0 pg/mL in both cohorts). ( c , d ) Heat maps summarizing individual cytokine response to AfuLy in all 14 patients. ( e ) Comparison of individual AfuLy-induced concentrations of selected T-helper cell signature cytokines. Medians and interquartile ranges for patients with ABPA/CF/CPA (“A”, red) and controls (“C”, grey) are indicated by black bars and colored boxes, respectively. Two-sided Mann–Whitney U test. Abbreviations: AfuLy = A. fumigatus mycelial lysate, ABPA = allergic bronchopulmonary aspergillosis, CF = cystic fibrosis, CPA = chronic pulmonary aspergillosis, Fractalk. = fractalkine, WB = whole blood.

Article Snippet: The Whole Blood Column Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) was applied to a MidiMACSTM cell separator (Miltenyi Biotec, Bergisch Gladbach, Germany) and rinsed with PBS (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 0.5% human AB serum (Sigma-Aldrich, St. Louis, MO, USA).

Techniques: Comparison, Control, Clinical Proteomics, Luminex, MANN-WHITNEY

Journal:

Article Title: Preclinical and Clinical Performance of the Efoora Test, a Rapid Test for Detection of Human Immunodeficiency Virus-Specific Antibodies

doi: 10.1128/JCM.43.5.2399-2406.2005

Figure Lengend Snippet: Efoora HIV rapid test preclinical testing locations and information

Article Snippet: Specimens tested at sites 2 and 4 were predominantly, if not exclusively, from patients whose infection originated in the United States and thus were probably subtype B. table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Site Date No. of specimens tested Reference test(s) a Specimen type(s) U.S. East Coast March 1999 1,931 Genetic Systems HIV-1/2, Bio-Rad WB Serum February 2000 291 Genetic Systems HIV-1/2, Genetic Systems rLAV EIA, Bio-Rad WB Fresh whole blood February 2001 528 Genetic Systems HIV-1/2, Bio-Rad WB Serum, plasma, whole blood U.S. Midwest June 1999 1,076 Genetic Systems HIV-1/2, Abbott HIV-1/2, Bio-Rad WB Serum, plasma Ivory Coast, West Africa June 1999 962 Enzygnost Plus, immunocapture HIV Serum, plasma South Africa March 2000 150 Genetic Systems HIV-1/2 Serum, plasma, whole blood Open in a separate window a rLAV, recombinant lymphadenopathy-associated virus (HIV-1).

Techniques: